Moxifloxacin prophylaxis in neutropenic patients

Moxifloxacin prophylaxis in neutropenic patients.

OBJECTIVES Recent studies have shown a beneficial impact of fluoroquinolones on infection-related morbidity and mortality for patients with haematological malignancies during neutropenia. Among the fluoroquinolones moxifloxacin currently provides one of the broadest spectra of antibacterial activity and may be suitable for prophylaxis during neutropenia. PATIENTS AND METHODS In this controlle...

Antibiotic prophylaxis in neutropenic patients.

The Role of Quinolones as Prophylaxis in Neutropenic Patients

Neutropenia and risk of infectious complications It has been appreciated for 50 years that neutropenia predisposes patients to infectious diseases. The degree and duration of neutropenia predict the risk of infectious complications, and resolution of infections is linked to myeloid recovery (1). Chemotherapy-related oral and gastrointestinal mucositis play an important role in contributing to t...

Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.

BACKGROUND Bacterial infections are a major cause of illness and death in patients who are neutropenic after chemotherapy treatment for cancer. Trials have shown the efficacy of antibiotic prophylaxis in decreasing the incidence of bacterial infections but not in reducing mortality rates. PURPOSE To evaluate whether antibiotic prophylaxis in neutropenic patients reduces mortality and incidenc...

Antibacterial prophylaxis in neutropenic children with cancer

During the period of neutropenia induced by chemotherapy, patients have a high risk of infection. The use of antibiotic prophylaxis to reduce neutropenia-related complications in patients with cancer is still disputed. Recent meta-analysis and clinical trials demonstrated that antibiotic prophylaxis with quinolones reduces febrile episodes, bacterial infections and mortality in adult oncologica...